Medical Tourism in China for Advanced Care: Hospitals, Costs, and Logistics
- MedBridgeNZ
- 1 hour ago
- 7 min read
When patients and their treating clinicians are concerned that local treatment delays may affect care, obtaining an additional specialist review from a tertiary hospital overseas may be considered as one possible pathway. Within many public health systems, capacity bottlenecks have led to significant delays in accessing specialty care. Public health data from New Zealand in 2025, for example, reported that only 63.9% of patients met the four-month target for elective surgery [1]. For individuals awaiting complex oncology resections or systemic therapies, these prolonged delays may create additional clinical and practical risks, including the possibility of disease progression in some patients.
For international patients, exploring advanced care in China requires navigating institution-specific clinical and administrative requirements.
Quick Answer: What to Expect from the Advanced-Care Pathway
China offers several advanced-care pathways for eligible international patients, including NMPA-approved CAR-T products, established proton therapy, specialized carbon-ion therapy, and selected investigational cellular therapies. Access is case-specific and depends on independent hospital review. Self-paying patients should expect advance-payment requirements, written hospital estimates, medical-record preparation, and visa and travel planning before treatment.
Establishing an administratively coordinated pathway helps align medical records with the receiving institution’s stated intake requirements. The primary logistical avenues include:
Translating and formatting pathology reports for institutional review.
Submitting structured clinical records to the receiving hospital for specialist or multidisciplinary review.
Scheduling targeted therapies or consultations, subject to the receiving institution's schedule and acceptance.
Not Sure Whether Your Records Are Ready? Submit your available treatment summary, pathology reports, and imaging index for an administrative completeness check. We can identify commonly missing documents and explain the preparation and submission process.
Administrative completeness check only. This is not a clinical assessment, diagnosis, or treatment recommendation.
Approved, Established, and Investigational Treatment Pathways in China
The healthcare landscape in China features highly stratified institutions offering both established and newly approved interventions. Access to these interventions is subject to strict institutional eligibility criteria.
Satri-cel (CT041)
This is a CAR-T product approved in China by the NMPA on June 22, 2026 [2, 3]. It is approved for eligible patients with CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma following at least two prior lines of systemic therapy [4]. In its Phase II clinical study, the therapy demonstrated a median progression-free survival of 3.25 months compared to 1.77 months in the standard care cohort, and a median overall survival of 7.92 months versus 5.49 months [3, 4]. Center-level availability requires confirmation, and availability in China does not represent approval in every jurisdiction.
ICG318 Dual-Target Therapy
This is an investigational dual-target CAR-T approach designed to target CD19-positive B cells and BCMA-positive plasma cells [5, 6]. Early results were reported in a small cohort of 12 patients with refractory systemic lupus erythematosus (SLE) or lupus nephritis [5]. In this specific cohort, 10 of the 12 treated participants met the study-defined criteria for strict complete remission [5]. These findings are preliminary, should not be generalized to broader patient populations, and do not establish the therapy as standard care.
Proton Therapy
An established form of particle radiotherapy used for selected clinical indications. Eligibility depends on tumor type, location, prior radiation exposure, and the receiving center’s assessment.
Carbon-Ion (Heavy-Ion) Therapy
A specialized form of particle radiotherapy available at a limited number of dedicated centers [7]. Evidence maturity and clinical suitability vary by tumor type, and eligibility must be determined by the treating radiation oncology team.
Note: Patients with rapidly deteriorating disease, significant organ dysfunction, or urgent care needs should obtain individualized medical and fitness-to-travel advice from their treating clinicians before considering long-distance travel. MedBridgeNZ does not determine treatment eligibility or fitness to fly.
Treatment Costs and Possible Exclusions
Many Chinese hospitals require advance payment, deposits, or account top-ups before certain consultations, investigations, medicines, or inpatient services [8]. Payment procedures vary by hospital, department, and patient category.
Below are broad planning ranges compiled from publicly available hospital information, manufacturer disclosures, published healthcare analyses, and industry estimates for self-paying international patients. Where available, MedBridgeNZ can coordinate requests for written hospital estimates and help organize the expected cost components for the patient. Hospital charges, treatment inclusions, and clinical estimates are determined by the receiving institution. MedBridgeNZ coordination fees are separate from hospital, physician, medicine, laboratory, travel, and accommodation costs.
Treatment Pathway | Illustrative Planning Range (USD) | Potential Components—Confirm in Written Hospital Estimate | Source |
Commercial CAR-T | $135,000 - $200,000 | Cell product, admission, standard monitoring | [9-12] |
Proton Therapy | $38,000 - $55,000 | Planning and scheduled fractions | [13] |
Carbon-Ion (Heavy-Ion) Therapy | $45,000 - $60,000 | Treatment planning and delivery | [13] |
The commercial CAR-T range above aggregates planning information concerning different products and treatment pathways. It should not be interpreted as a published price for Satri-cel or as a quotation for any specific CAR-T product.
Cost notice: These figures are broad planning ranges compiled from cited third-party estimates and are not hospital quotations, guaranteed package prices, or estimates for a specific patient. A written estimate should be requested from the receiving institution before the patient commits to treatment or international travel. Depending on the treatment and hospital, quoted costs may exclude pre-treatment assessment, leukapheresis, bridging therapy, repeat pathology or imaging, medicines, ICU care, complication management, extended admission, travel, and accommodation.
Visa and Travel Logistics
Depending on the patient’s nationality, intended length of stay, treatment schedule, and supporting documentation, an S2 visa or another appropriate visa or visa-free entry arrangement may be considered. The S2 category generally applies to certain short-term private affairs involving an intended stay of no more than 180 days; the visa type, permitted duration, and required documentation are determined by the relevant Chinese authorities. Patients should confirm the appropriate entry pathway with the responsible Chinese embassy, consulate, or visa application center before travel.
This information is general administrative guidance and does not constitute immigration or legal advice.
Examples of Chinese Medical Centers With International Patient Services
The following examples are illustrative, not exhaustive, and do not constitute a ranking or clinical recommendation.
International medical access is predominantly facilitated through specific, designated international departments within tertiary hospitals.
Shanghai Proton and Heavy Ion Center (SPHIC): A dedicated particle therapy facility equipped to deliver specialized radiation for anatomically complex tumors [7, 14].
Shanghai Ruijin Hospital International Department: Based on a MedBridgeNZ site review, the facility includes 32 private consultation rooms, on-site blood collection, access to ultrasound, CT, and MRI services, and a designated international insurance settlement area [15]. Facilities, available services, and insurer arrangements should be reconfirmed before admission.
Representative Administrative Pathway
The following pathway is illustrative of the logistical flow for international clients:
Initial Case Intake: The patient's local clinical files are securely compiled. We facilitate professional administrative compilation and translation.
Institutional Submission Coordination: Once the administrative service scope and applicable coordination fee have been confirmed, MedBridgeNZ can submit the prepared records through the receiving institution’s stated intake process or international-patient contact channel, where available and subject to the institution accepting the submission. Any clinical review, eligibility decision, recommendation, and treatment plan is determined independently by the receiving hospital’s clinical team.
On-the-Ground Coordination: If the receiving hospital accepts the case and the patient decides to proceed after consultation with their treating clinicians, our administrative teams manage ground logistics. This includes navigating real-name registration networks and coordinating bilingual on-site interpretation support.
Frequently Asked Questions
1. What clinical records may be requested for a remote review of advanced gastric cancer?
Receiving institutions may request recent imaging in DICOM format, relevant pathology reports, a complete systemic treatment history, and available biomarker results, such as HER2, CLDN18.2, PD-L1, or mismatch-repair testing where clinically relevant. The exact document list depends on the hospital, disease stage, and purpose of the review.
2. How does the translation process work for complex biomarker reports before institutional submission?
Relevant biomarker reports, treatment summaries, pathology records, and supporting terminology are translated and structurally formatted as required by the receiving institution. Patients should also retain their original, untranslated medical files because the receiving hospital may require them for clinical verification.
3. What factors affect eligibility for proton or carbon-ion therapy?
Eligibility criteria vary by center and indication and may include tumor type, location, prior treatment, organ function, and the patient’s ability to complete simulation and treatment positioning. Final eligibility is determined by the receiving center’s radiation oncology team.
4. How do international commercial insurance networks interface with Chinese tertiary hospitals?
Some designated international departments may maintain direct-billing arrangements with selected international insurers. Coverage, pre-authorization requirements, and hospital participation must be confirmed with both the insurer and the hospital before treatment. Patients using standard public pathways may need to pay first and seek reimbursement afterward.
5. Can visas be extended if post-treatment monitoring requires a longer stay?
Any extension is discretionary and subject to approval by the relevant Chinese immigration authority. Hospital documentation may support an application but does not guarantee approval.
6. How do patients navigate the language barrier during highly complex surgical consultations?
MedBridgeNZ can coordinate bilingual administrative support and help arrange qualified interpretation where available. The treating hospital and clinicians remain responsible for clinical explanations, treatment recommendations, and obtaining informed consent.
Need help preparing records for hospital submission? Start with an administrative completeness check to identify commonly missing documents and understand the next procedural steps.
Administrative completeness check only. This is not a clinical assessment, diagnosis, or treatment recommendation.
References
Hospital Health Target Scores Update - Grey Power New Zealand Federation Inc. Retrieved from https://www.greypower.co.nz/news/hospital-health-target-scores-update
China approves world's first CAR-T therapy for solid tumors. Cell Gene Therapy Review. Retrieved from https://www.cellgenetherapyreview.com/3972-News/626338-China-approves-world-s-first-CAR-T-therapy-for-solid-tumors/
China Approves Satri-cel, the World's First CAR-T Therapy for Solid Tumors. Oncodaily. Retrieved from https://oncodaily.com/industry/car-t-china
CT041 (Satri-Cel): World's First Approved CAR-T for Solid Tumours. ChinaMed Waypoint. Retrieved from https://chinamedwaypoint.com/resources/cancer-care/cancer-care-in-china/car-t-cell-therapy/ct041-satri-cel-cldn18-2-gastric-cancer-nmpa-approval
Breakthrough in dual-target CAR-T therapy for refractory SLE. Zhejiang University School of Medicine. Retrieved from http://www.cmm.zju.edu.cn/cmmenglish/2026/0120/c52911a3129858/pagem.htm
BCMA-CD19 armored compound CAR T cells in systemic lupus erythematosus: extended follow-up of a phase 1 clinical trial. PubMed. Retrieved from https://pubmed.ncbi.nlm.nih.gov/41612420/
Shanghai Proton & Heavy Ion Center: Advanced Cancer Radiation Therapy. MedBridgeNZ. Retrieved from https://www.medbridgenz.com/sphic-hospital
China Healthcare Insights & Patient Guides. MedBridgeNZ. Retrieved from https://www.medbridgenz.com/blog
CAR-T Therapy Cost in China: 2026 Price Comparison. Sylk Health. Retrieved from https://sylkhealth.com/blog/articles/car-t-therapy-cost-china
CAR-T Therapy in China: Costs, Hospitals & 2026 Patient Guide. MedBridgeNZ. Retrieved from https://www.medbridgenz.com/post/car-t-therapy-china-cost-quide-2026
CAR-T Cell Therapy Cost in China vs USA: 2026 Comparison Guide. China Care Health Tours. Retrieved from https://chinacarehealthtours.com/car-t-cell-therapy-cost-in-china-vs-usa-2026-comparison-guide/
How Much Does CAR-T Cost in China for International Patients? ChinaMed Waypoint. Retrieved from https://chinamedwaypoint.com/resources/cancer-care/treatment-explained/car-t-cost-china
Cancer Treatment Cost China vs US: Save 50-85% (2026). Sylk Health. Retrieved from https://sylkhealth.com/blog/articles/cancer-treatment-china-cost
Shanghai Proton and Heavy Ion Center (SPHIC). China Care Health Tours. Retrieved from https://chinacarehealthtours.com/hospitals/shanghai/sphic/
Ruijin Hospital International Department: Insider Review. MedBridgeNZ. Retrieved from https://www.medbridgenz.com/post/medical-tourism-china-ruijin-hospital-international-department-review
Written by: MedBridgeNZ Patient Coordination Team
Sources and regulatory information last checked: July 2026
Cost information last checked: July 2026
Disclaimer: MedBridgeNZ is a medical concierge and logistics coordination service. We do not provide medical advice, diagnosis, or treatment, and we do not determine clinical eligibility or fitness to travel. This content is provided for general informational purposes only. Hospital acceptance, specialist availability, treatment access, costs, visa decisions, and clinical outcomes are determined by the relevant institutions and authorities and cannot be guaranteed. Always consult your treating physician before considering cross-border care.